|
US4866034A
(en)
|
1982-05-26 |
1989-09-12 |
Ribi Immunochem Research Inc. |
Refined detoxified endotoxin
|
|
US4436727A
(en)
|
1982-05-26 |
1984-03-13 |
Ribi Immunochem Research, Inc. |
Refined detoxified endotoxin product
|
|
US4987237A
(en)
|
1983-08-26 |
1991-01-22 |
Ribi Immunochem Research, Inc. |
Derivatives of monophosphoryl lipid A
|
|
US4877611A
(en)
|
1986-04-15 |
1989-10-31 |
Ribi Immunochem Research Inc. |
Vaccine containing tumor antigens and adjuvants
|
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
|
US4912094B1
(en)
|
1988-06-29 |
1994-02-15 |
Ribi Immunochem Research Inc. |
Modified lipopolysaccharides and process of preparation
|
|
HU212924B
(en)
|
1989-05-25 |
1996-12-30 |
Chiron Corp |
Adjuvant formulation comprising a submicron oil droplet emulsion
|
|
JPH0655749B2
(ja)
|
1989-09-20 |
1994-07-27 |
日本たばこ産業株式会社 |
リピッドａ単糖類縁体
|
|
US5370872A
(en)
|
1991-08-12 |
1994-12-06 |
Swiss Serum And Vaccine Institute Berne |
Escherichia coliO-polysaccharide-protein conjugate vaccine
|
|
US5593969A
(en)
|
1991-09-03 |
1997-01-14 |
Igen Incorporated |
Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
|
|
DK0671948T3
(da)
|
1992-06-25 |
1997-09-01 |
Smithkline Beecham Biolog |
Vaccinepræparat indeholdende adjuvanser
|
|
UA56132C2
(uk)
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
|
|
US6491919B2
(en)
|
1997-04-01 |
2002-12-10 |
Corixa Corporation |
Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
|
|
NZ338101A
(en)
|
1997-04-01 |
2002-03-28 |
Corixa Corp |
Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
|
|
US6500434B1
(en)
|
1998-04-23 |
2002-12-31 |
Medimmune, Inc. |
Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
|
|
US6858211B1
(en)
|
1998-07-20 |
2005-02-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vaccines against Escherichia coli O157 infection
|
|
DE69935606T9
(de)
|
1998-10-16 |
2021-03-11 |
Glaxosmithkline Biologicals S.A. |
Adjuvanzsysteme und impfstoffe
|
|
US6759241B1
(en)
|
1999-10-04 |
2004-07-06 |
University Of Maryland Biotechnology Institute |
Adjuvant comprising a lipopolysaccharide antagonist
|
|
WO2001078777A2
(en)
|
2000-04-13 |
2001-10-25 |
Mossman, Sally |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
|
|
EP1299544A2
(en)
|
2000-07-07 |
2003-04-09 |
Medimmune, Inc. |
Fimh adhesin proteins and methods of use
|
|
EP1313502A4
(en)
|
2000-08-18 |
2005-10-19 |
Medimmune Inc |
ADMINISTRATIVE PROCEDURE OF FIMH PROTEIN AS A VACCINE AGAINST HARNWAY INFECTIONS
|
|
US20030199071A1
(en)
|
2000-12-08 |
2003-10-23 |
Solomon Langermann |
Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
|
|
US6676958B2
(en)
|
2001-06-19 |
2004-01-13 |
Advanced Bioadjuvants, Llc |
Adjuvant composition for mucosal and injection delivered vaccines
|
|
EP1874342B1
(en)
|
2005-04-26 |
2018-06-06 |
Eisai R&D Management Co., Ltd. |
Compositions and methods for cancer immunotherapy
|
|
CA2607595C
(en)
|
2005-05-11 |
2018-11-27 |
Eth Zuerich |
Recombinant n-glycosylated proteins from procaryotic cells
|
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
|
CA2646891A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
|
HRP20181259T1
(hr)
|
2008-02-20 |
2018-10-05 |
Glaxosmithkline Biologicals S.A. |
Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
|
|
CN102481312B
(zh)
|
2009-06-05 |
2015-07-15 |
传染性疾病研究院 |
合成的吡喃葡萄糖脂佐剂
|
|
PL2811981T3
(pl)
|
2012-02-07 |
2019-09-30 |
Infectious Disease Research Institute |
Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
|
|
RS59500B1
(sr)
|
2013-05-18 |
2019-12-31 |
Aduro Biotech Inc |
Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
|
|
US9415101B2
(en)
|
2013-09-25 |
2016-08-16 |
Sequoia Sciences, Inc. |
Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
|
|
US9504743B2
(en)
|
2013-09-25 |
2016-11-29 |
Sequoia Sciences, Inc |
Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
|
|
US20150086592A1
(en)
|
2013-09-25 |
2015-03-26 |
Sequoia Sciences, Inc |
Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
|
|
US9149522B2
(en)
*
|
2013-09-25 |
2015-10-06 |
Sequoia Sciences, Inc. |
Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
|
|
US9415097B2
(en)
|
2013-09-25 |
2016-08-16 |
Sequoia Sciences, Inc. |
Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
|
|
US9149521B2
(en)
|
2013-09-25 |
2015-10-06 |
Sequoia Sciences, Inc. |
Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
|
|
CN106535927B
(zh)
|
2014-02-24 |
2019-09-20 |
葛兰素史密丝克莱恩生物有限公司 |
新颖多糖及其用途
|
|
EP3294761A4
(en)
*
|
2015-05-13 |
2019-04-03 |
University of Washington |
COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF UROPATHOGEN E. COLI
|
|
ES2839880T3
(es)
|
2015-07-07 |
2021-07-06 |
Janssen Vaccines & Prevention Bv |
Vacuna contra el VRS
|
|
TWI715617B
(zh)
|
2015-08-24 |
2021-01-11 |
比利時商葛蘭素史密斯克藍生物品公司 |
對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
|
|
US20190275134A1
(en)
|
2018-03-12 |
2019-09-12 |
Janssen Pharmaceuticals, Inc |
Vaccines against urinary tract infections
|
|
US20240027467A1
(en)
|
2019-12-20 |
2024-01-25 |
Vib Vzw |
Nanobody Exchange Chromatography
|
|
LT4090363T
(lt)
|
2020-01-16 |
2024-09-25 |
Janssen Pharmaceuticals, Inc. |
Fimh mutantas, kompozicijos su juo ir jų panaudojimas
|
|
US11725028B2
(en)
|
2021-01-12 |
2023-08-15 |
Janssen Pharmaceuticals, Inc. |
FimH mutants, compositions therewith and use thereof
|